SNSE - Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference | Benzinga
- New data from multi-dose GLP toxicology study of SNS-101 in cynomolgus monkeys further support exceptional PK and safety profile -
- Mechanistic mouse data show SNS-101 drives tumor macrophages to adopt an immunostimulatory, anti-tumor phenotype -
BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today will present new preclinical data from SNS-101, a clinical-stage conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Seventh Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held on September 20 – 23, 2023 in Milan, Italy.
"We believe these data further support the potential best-in-class PK and safety profile of SNS-101 and its ability to effectively target VISTA, a promising, but difficult-to-drug immune checkpoint," said Edward van der Horst, Ph.D., Chief Scientific Officer of Sensei Biotherapeutics. "Restricting drug activity to low pH conditions, such as those found in the acidic tumor microenvironment, allowed us to safely dose SNS-101 in our multi-dose NHP study at increasing levels while maintaining linear elimination kinetics and displaying no target-mediated drug disposition or adverse effects. Paired with new mechanistic data showing SNS-101 can shift immunosuppressive macrophages towards an anti-tumor phenotype, we believe SNS-101 could provide a transformative treatment option for patients. We look forward to sharing data from our ongoing clinical trial later this year."
Presentation Highlights:
- SNS-101 displayed linear elimination kinetics and no target-mediated drug disposition or adverse effects in a multi-dose GLP toxicology study in cynomolgus monkeys evaluating SNS-101 doses of 1, 10 and 100 mg/kg.
- In MC38 tumor-bearing mice, SNS-101 alone and in combination with an anti-PD-1 antibody shifted the ...